Stephan Von Schilcher, global strategic account manager at Systech, discusses the repercussions of counterfeit drug epidemic on patients and what pharma companies must to combat the problem.
In an interview following FACHPACK, editor Rebekah Jordan caught up with Sharon Barak, president and co-founder of Solutum, on the reasons behind their partnership with pester pac and the wider pharma packaging challenges it addresses.
The CPHI Annual Industry Survey reveals that the pharma sector is on the cusp of a major shift, with approvals for complex molecules expected to outpace those for small molecules for the first time.
David Blanco, Industrial BD & CDMO director, Suanfarma, shares how the pharma industry can enhance innovation by combining biofermentation and chemical synthesis, while highlighting the importance of technology transfer for implementation of both.
Ahead of CPHI Milan, EPM spoke to Thierry Van Nieuwenhove, CEO of Quotient Sciences, to explore how the company is innovating to meet the growing demand for personalised medicine through AI, partnerships and meeting sustainability goals.
Ahead of CPHI Milan, EPM spoke to Hayley Crowe, executive vice president and general manager of Ecolab's Global Life Sciences sector, to discuss the company's approach to addressing the growing demand of cell and gene therapies (C>s).
Semaglutide usage has surged in recent years due to FDA approval for its wider usage in weight loss management, providing a legal and regulated avenue for the drug to be prescribed.
Renato Rjavec, ArisGlobal, discusses how generative AI (GenAI) technology is transforming everyday regulatory and safety processes, thanks to its ability to summarise key insights and findings from across huge, diverse bodies of content and data.
Modern pharma brands pursue a higher degree of content personalisation to engage with diverse audiences. This means tighter deadlines, higher workloads, and a greater demand for skilled content creators than ever before.
